Previous 10 | Next 10 |
2024-01-04 06:51:53 ET More on Zymeworks Zymeworks: Late-Stage Study Data In 2024 Makes This A Must-Watch Zymeworks lays out 2024 and 2025 outlook Zymeworks to raise ~$50M For further details see: Zymeworks names Jeffrey Smith as Chief Medical Officer
2024-01-04 06:37:19 ET More on Zymeworks Zymeworks: Late-Stage Study Data In 2024 Makes This A Must-Watch Zymeworks to raise ~$50M Zymeworks Q3 2023 Earnings Preview For further details see: Zymeworks lays out 2024 and 2025 outlook
Company well-positioned for further progress and broadening of R&D pipeline Cash resources of approximately $455 million as of December 31, 2023 (unaudited) Expected cash runway, including proceeds from recent private placement, into 2H 2027 Top-line data readout fro...
Dr. Jeffrey Smith named Executive Vice President and Chief Medical Officer Dr. John Fann promoted to Senior VP, Process Sciences Seven new Vice Presidents appointed, underscoring commitment to leadership development VANCOUVER, British Columbia, Jan. 04, 2024 (GLOBE NEW...
2023-12-30 06:25:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-12-26 08:30:03 ET More on Zymeworks Zymeworks: Late-Stage Study Data In 2024 Makes This A Must-Watch Zymeworks Inc. 2023 Q3 - Results - Earnings Call Presentation Zymeworks Inc. (ZYME) Q3 2023 Earnings Call Transcript Zymeworks Q3 2023 Earnings Preview ...
VANCOUVER, British Columbia, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biopharmaceutical company developing novel, multifunctional biotherapeutics, today announced that it had entered into a securities purchase agreement with funds affiliated with EcoR1 Cap...
2023-12-21 07:24:53 ET Summary Jazz Pharmaceuticals' market valuation is fairly conservative overlooking its promising potential. Zanidatamab's Phase 2a success boosts Jazz's oncology market potential. Despite challenges, Jazz's strategic positioning and conservative market va...
VANCOUVER, British Columbia, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBIȁ...
2023-12-13 12:04:25 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The pandemic pushed major biotech stocks into the spotlight as vaccine demands rose to unprecedented highs. Investors flocked to the industry in the next few years after the COVID-19 breako...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that manage...
VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that the Un...
Pursuant to the terms of the licensing agreement between Zymeworks and BeiGene, Zymeworks is entitled to receive an $8 million milestone payment from BeiGene and remains eligible to receive up to $164 million based on additional milestones plus royalties on product sales A Biologics License A...